1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sihuan Pharmaceutical Holdings Group Ltd. (RVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical) is a prescription drug pharmaceutical company. It is holds expertise and carries out research, development, manufacturing and commercialization of cardiovascular and cerebral vascular drugs. The company offers a wide range of products in the therapeutic areas of cardiovascular system, nervous system, anti-infective, metabolism and oncology. Its cardio-cerebral vascular drug product portfolio includes Aoliankang, Yeduojia, Yuanzhijiu, Oudimei, Yimaining, Qingtong, Qu’ao, Chuanqing, Aogan and Kelinao/Anjieli; and other drugs include Luoanming, Pojia, Zhuo’ao/Bi’ao and Ren’ao, among others. The company’s research and developmental capabilities focuses on the development generic drugs. It has a network of over 3,000 distributors covering close to 10,000 hospitals and medical institutions across China. Sihuan is headquartered in Beijing, China.

Sihuan Pharmaceutical Holdings Group Ltd. (RVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Sihuan Pharmaceutical Holdings Group Ltd. (RVX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile
Table of Contents


Table of Contents 2

List of Tables
3

List of Figures
4
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deal Details 11
Asset Purchase 11
Jilin Sihuan To Acquire Technology Of Pidotimod Injection From Guangzhou Boji Pharma 11
Private Equity 12
China Pharma Acquires Sihuan Pharma Holdings Group 12
Partnerships 14
Sihuan Pharma Forms Joint Venture with MSPEA and Euromax 14
Sihuan Enters into Co-Development Agreement with Academy of Military Medical Sciences 15
Sihuan Pharma Enters into Co-Development Agreement with Academy of Military Medical Sciences 16
to-BBB Enters Into RandD Agreement With Sun Moral International 17
Sihuan Pharma Holdings Enters Into Co-Marketing Agreement With Benxi Leilong Pharma 18
Licensing Agreements 19
NeuroVive Pharma Enters Into Licensing Agreement With Sihuan Pharma For CicloMulsion And NeuroStat 19
Equity Offering 21
Sihuan Pharma Rumored For Public Offering Of Shares For US$147 Million 21
Sihuan Pharma Completes IPO Of US$741 Million 22
Acquisition 24
Morgan Stanley Private Equity Asia To Divest Stake In Sihuan Pharma For Upto US$146.4 Million 24
Sihuan Pharma Acquires 40% Stake in XuanZhu Pharma 25
Shandong Buchang Completes Acquisition Of 19% Stake In Jilin Sichang Pharma For US$37 Million 26
Sihuan Pharma Completes Acquisition Of 100% Stake In Smart Baskets Investments From Congio Enterprises 28
Jilin Sihuan Pharma Completes Acquisition Of 80% Stake In Changchun Xiangtong Pharma For US$21 Million 30
Sihuan Pharma Completes Acquisition Of Dupromise From JSAB Investment For Upto US$361 Million 32
Jing Shi Li Mai Acquires 27.8% Stake In Beijing Purenhong Pharma From Sihuan Pharma Holdings Group 34
Sihuan Pharmaceutical Holdings Group Ltd. - Key Competitors 35
Key Employees 36
Locations And Subsidiaries 37
Head Office 37
Other Locations and Subsidiaries 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38


List of Tables

Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Key Facts, 2013 1
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Sihuan Pharmaceutical Holdings Group Ltd., Deals By Therapy Area, 2009 to YTD 2015 8
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Jilin Sihuan To Acquire Technology Of Pidotimod Injection From Guangzhou Boji Pharma 11
China Pharma Acquires Sihuan Pharma Holdings Group 12
Sihuan Pharma Forms Joint Venture with MSPEA and Euromax 14
Sihuan Enters into Co-Development Agreement with Academy of Military Medical Sciences 15
Sihuan Pharma Enters into Co-Development Agreement with Academy of Military Medical Sciences 16
to-BBB Enters Into RandD Agreement With Sun Moral International 17
Sihuan Pharma Holdings Enters Into Co-Marketing Agreement With Benxi Leilong Pharma 18
NeuroVive Pharma Enters Into Licensing Agreement With Sihuan Pharma For CicloMulsion And NeuroStat 19
Sihuan Pharma Rumored For Public Offering Of Shares For US$147 Million 21
Sihuan Pharma Completes IPO Of US$741 Million 22
Morgan Stanley Private Equity Asia To Divest Stake In Sihuan Pharma For Upto US$146.4 Million 24
Sihuan Pharma Acquires 40% Stake in XuanZhu Pharma 25
Shandong Buchang Completes Acquisition Of 19% Stake In Jilin Sichang Pharma For US$37 Million 26
Sihuan Pharma Completes Acquisition Of 100% Stake In Smart Baskets Investments From Congio Enterprises 28
Jilin Sihuan Pharma Completes Acquisition Of 80% Stake In Changchun Xiangtong Pharma For US$21 Million 30
Sihuan Pharma Completes Acquisition Of Dupromise From JSAB Investment For Upto US$361 Million 32
Jing Shi Li Mai Acquires 27.8% Stake In Beijing Purenhong Pharma From Sihuan Pharma Holdings Group 34
Sihuan Pharmaceutical Holdings Group Ltd., Key Competitors 35
Sihuan Pharmaceutical Holdings Group Ltd., Key Employees 36
Sihuan Pharmaceutical Holdings Group Ltd., Subsidiaries 37


List of Figures

Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 1
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 1
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 1
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 6
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Sihuan Pharmaceutical Holdings Group Ltd., Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8

Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.